Manyi Xu

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 6

Top Topics

Tyrosine Kinase

Liver Metastases

Genome Wide Identification

Chronic Myeloid Leukemia

Top Venues

Therapeutic advances in medical oncology

Cancer medicine

Investigational new drugs

This page only lists publications with an associated author ORCID identifier.

Publications

Yanhua Wang, Manyi Xu, Ke Wang, Yue Hao, Chunwei Xu, Zhengbo Song
Assessment of efficacy and safety of MET tyrosine kinase inhibitors in non-small-cell lung cancer patients with MET alterations. Therapeutic advances in medical oncology 16 (2024)
Yue Hao, Manyi Xu, Xiaohong Zeng, Yina Wang, Wenxian Wang, Gen Lin, Bihui Li, Jianhui Huang, Chunwei Xu, Yongchang Zhang, Zhengbo Song
Poor efficacy of immune checkpoint inhibitor treatment in advanced thymic carcinoma patients with liver metastases. Therapeutic advances in medical oncology 16 (2024)
Yue Hao, Manyi Xu, Xiaohong Zeng, Yina Wang, Wenxian Wang, Gen Lin, Bihui Li, Jianhui Huang, Chunwei Xu, Yongchang Zhang, Zhengbo Song
Poor efficacy of immune checkpoint inhibitor treatment in advanced thymic carcinoma patients with liver metastases. Therapeutic advances in medical oncology 16 (2024)
Yanhua Wang, Manyi Xu, Ke Wang, Yue Hao, Chunwei Xu, Zhengbo Song
Assessment of efficacy and safety of MET tyrosine kinase inhibitors in non-small-cell lung cancer patients with MET alterations. Therapeutic advances in medical oncology 16 (2024)
Lan Xu, Manyi Xu, Wei Sun, Weiping Zhang, Zhengbo Song
Clinical characteristics and prognostic impact of immune checkpoint inhibitor-associated myocarditis in advanced non-small cell lung cancer. Investigational new drugs (2023)
Yue Hao, Manyi Xu, Jianan Jin, Jinfei Si, Chun-Wei Xu, Zhengbo Song
Comparison of efficacy and safety of second- and third-generation TKIs for non-small-cell lung cancer with uncommon EGFR mutations. Cancer medicine (2023)